Overlapping paclitaxel-eluting stents: long-term effects in a porcine coronary artery model
- PMID: 17716637
- DOI: 10.1016/j.cardiores.2007.07.004
Overlapping paclitaxel-eluting stents: long-term effects in a porcine coronary artery model
Abstract
Objective: At 4-year follow-up, paclitaxel-eluting stents (PES, TAXUS) have demonstrated clinical effectiveness in reducing restenosis without increasing death or myocardial infarction. Concerns remain with all drug-eluting stents, however, regarding potential interference with long-term healing, particularly in zones with adjacent stent overlap due to theoretical doubling in both drug release and tissue contact with coating polymer. Therefore, we evaluated long-term healing of overlapped TAXUS stents in an accepted animal model.
Methods: Seventy-one non-injured swine underwent coronary artery placement of 138 overlapping stent-pairs (91 PES TAXUS Liberté 1 microg/mm(2) slow release formulation, 3.0 or 3.5 mm diameter pairs and 47 control bare metal Liberté pairs) deployed at a 1.1:1 to 1.2:1 target stent-to-artery diameter ratio. Pathological analysis was performed at 30 (9 bare, 10 paclitaxel), 90 (9 bare, 10 paclitaxel), 180 (10 bare, 16 paclitaxel), 360 (10 bare, 21 paclitaxel), and 580 (9 bare, 22 paclitaxel) days.
Results: At all time intervals overlapped TAXUS stents were consistently endothelialized and free of luminal thrombus or vascular dilatation. Full healing, however, was delayed compared to control, with macrophage processed para-strut fibrin and cellular debris still present, but reduced and sequestered from blood flow by an endothelialized neointima at 360 and 580 days. While neointimal thickness in TAXUS overlap zones was significantly less than control at 30 days, greater neointima formation was observed with TAXUS at > or =90 days, but was stable and did not progress further from 90 to 580 days.
Conclusion: In this porcine model TAXUS stents demonstrated safety and acceptable healing with prolonged time to resolution of para-strut deposits, and did not produce the sustained neointimal suppression seen clinically.
Similar articles
-
Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries.Circulation. 2009 Jul 14;120(2):141-9, 1-2. doi: 10.1161/CIRCULATIONAHA.107.730010. Epub 2009 Jun 29. Circulation. 2009. PMID: 19564562
-
Time dependent vascular and myocardial responses of a second generation, small vessel, paclitaxel-eluting stent platform.Catheter Cardiovasc Interv. 2009 Apr 1;73(5):597-604. doi: 10.1002/ccd.21890. Catheter Cardiovasc Interv. 2009. PMID: 19180652
-
Early vascular response to overlapped paclitaxel-eluting stents in swine coronary arteries.Cardiovasc Revasc Med. 2007 Oct-Dec;8(4):251-8. doi: 10.1016/j.carrev.2007.08.002. Cardiovasc Revasc Med. 2007. PMID: 18053947
-
The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents.Am J Cardiol. 2007 Oct 22;100(8B):36M-44M. doi: 10.1016/j.amjcard.2007.08.020. Am J Cardiol. 2007. PMID: 17950831 Review.
-
Comparative pathology: radiation-induced coronary artery disease in man and animals.Semin Interv Cardiol. 1998 Sep-Dec;3(3-4):163-72. Semin Interv Cardiol. 1998. PMID: 10406688 Review.
Cited by
-
Safety and efficacy of overlapping homogenous drug-eluting stents in patients with acute myocardial infarction: results from Korea Acute Myocardial Infarction Registry.J Korean Med Sci. 2012 Nov;27(11):1339-46. doi: 10.3346/jkms.2012.27.11.1339. Epub 2012 Oct 30. J Korean Med Sci. 2012. PMID: 23166415 Free PMC article.
-
Drug-eluting stents in preclinical studies: updated consensus recommendations for preclinical evaluation.Circ Cardiovasc Interv. 2008 Oct;1(2):143-53. doi: 10.1161/CIRCINTERVENTIONS.108.789974. Circ Cardiovasc Interv. 2008. PMID: 20031669 Free PMC article.
-
Outcomes of stenting with overlapping drug-eluting stents versus overlapping drug-eluting and bare-metal stents for the treatment of diffuse coronary lesions.Cardiovasc J Afr. 2010 Nov-Dec;21(6):311-5. doi: 10.5830/cvja-2010-004. Cardiovasc J Afr. 2010. PMID: 21135978 Free PMC article.
-
Atlas Drug-Eluting Coronary Stents Inhibit Neointimal Hyperplasia in Sheep Modeling.Acta Cardiol Sin. 2024 Sep;40(5):585-594. doi: 10.6515/ACS.202409_40(5).20240618A. Acta Cardiol Sin. 2024. PMID: 39308654 Free PMC article.
-
Comparative vascular responses three months after paclitaxel and everolimus-eluting stent implantation in streptozotocin-induced diabetic porcine coronary arteries.Cardiovasc Diabetol. 2012 Jun 21;11:75. doi: 10.1186/1475-2840-11-75. Cardiovasc Diabetol. 2012. PMID: 22716997 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources